Who are Bevacizumab + FOLFIRI-3's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): R-combination chemotherapy, R-CHOP; R-DA-EPOCH; R-HD MTX, Rituximab - CVP, R-miniCHOP, R-DA-EPOCH, Trastuzumab+ chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bevacizumab-folfiri-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Bevacizumab + FOLFIRI-3 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab + FOLFIRI-3 (Bevacizumab + FOLFIRI-3) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody + chemotherapy combination. Area: Oncology.

phase 3 Monoclonal antibody + chemotherapy combination VEGF (bevacizumab); Thymidylate synthase and topoisomerase I (FOLFIRI-3) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bevacizumab + FOLFIRI-3 (Bevacizumab + FOLFIRI-3) — AryoGen Pharmed Co.. Bevacizumab blocks VEGF to inhibit tumor angiogenesis, while FOLFIRI-3 (fluorouracil, leucovorin, and irinotecan) provides chemotherapy-induced DNA damage and cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bevacizumab + FOLFIRI-3 TARGET	Bevacizumab + FOLFIRI-3	AryoGen Pharmed Co.	phase 3	Monoclonal antibody + chemotherapy combination	VEGF (bevacizumab); Thymidylate synthase and topoisomerase I (FOLFIRI-3)
R-combination chemotherapy	R-combination chemotherapy	Shandong Provincial Hospital	marketed	Monoclonal antibody + chemotherapy combination	CD20
R-CHOP; R-DA-EPOCH; R-HD MTX	R-CHOP; R-DA-EPOCH; R-HD MTX	Shandong Provincial Hospital	phase 3	Monoclonal antibody + chemotherapy combination	CD20 (rituximab component)
Rituximab - CVP	Rituximab - CVP	The Lymphoma Academic Research Organisation	phase 3	Monoclonal antibody + chemotherapy combination	CD20
R-miniCHOP	R-miniCHOP	Universität des Saarlandes	phase 3	Monoclonal antibody + chemotherapy combination	CD20
R-DA-EPOCH	R-DA-EPOCH	Fujian Medical University	phase 3	Monoclonal antibody + chemotherapy combination	CD20
Trastuzumab+ chemotherapy	Trastuzumab+ chemotherapy	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	phase 3	Monoclonal antibody + chemotherapy combination	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody + chemotherapy combination class)

Fujian Medical University · 2 drugs in this class
Shandong Provincial Hospital · 2 drugs in this class
The Lymphoma Academic Research Organisation · 2 drugs in this class
Fondazione Italiana Linfomi - ETS · 2 drugs in this class
Nordic Lymphoma Group · 1 drug in this class
Prof. Dr. M. Dreyling (co-chairman) · 1 drug in this class
American Scitech International · 1 drug in this class
Universität des Saarlandes · 1 drug in this class
AryoGen Pharmed Co. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bevacizumab + FOLFIRI-3 — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-folfiri-3. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab